Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.74M | -26.19M | -29.55M | -24.81M | -25.65M |
| Total Depreciation and Amortization | 108.00K | 108.00K | 113.00K | 124.00K | 137.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.02M | 9.63M | 12.62M | 7.44M | 7.85M |
| Change in Net Operating Assets | -3.06M | -2.03M | -1.25M | 438.00K | 726.00K |
| Cash from Operations | -16.67M | -18.48M | -18.07M | -16.81M | -16.94M |
| Capital Expenditure | -35.00K | -35.00K | -16.00K | -1.00K | -1.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -35.00K | -35.00K | -16.00K | -1.00K | -1.00K |
| Total Debt Issued | 1.51M | 1.49M | 1.46M | 1.40M | -- |
| Total Debt Repaid | -70.00K | -69.00K | -67.00K | -123.00K | -67.00K |
| Issuance of Common Stock | 17.47M | 6.98M | 10.42M | 5.56M | 5.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -713.00K | 1.34M | 1.80M | 1.73M | -- |
| Cash from Financing | 18.19M | 9.74M | 13.61M | 8.57M | 5.50M |
| Foreign Exchange rate Adjustments | -92.00K | -167.00K | -44.00K | -1.00K | -132.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.40M | -8.94M | -4.53M | -8.25M | -11.57M |